Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (3108)	9/15/2005 4:03:58 PM
From: former_pgs	Read Replies (2) \| Respond to of 12215

>cytk is a good one, just not as good as it was 6 months ago.< Care to share why it's dropped a notch in your opinion? From the data you pointed to regarding the myosin activator compound, it looked from my perspective that things got slightly better.

To: keokalani'nui who wrote (3108)	9/15/2005 11:55:19 PM
From: rkrw	Respond to of 12215

You probably know a lot more than I do about dvax. Threw it out there more so on valuation and interest in TLR area than anything specific that I know. Going for 20X usually you have to think small. I could name a few more that are interesting with warts worse than dvax such as prw and glgs--long running battle between the two but a lot of people think the concept is sound; zona at $50M market cap is interesting imo. I do think the more intriguing bio's are private. Hopefully a few good ones escape the clutches of an easy buyout and ipo.